Physician profile
Vikram B Singh
NPI 1942401807
$15,827.15
in general payments reported to CMS, 2019-2025
46 companies · $3,335 in 2025
The $3,335 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,148 · 2020: $403 · 2021: $197 · 2022: $1,639 · 2023: $3,343 · 2024: $2,761 · 2025: $3,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,340 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,339.57 |
| Education | $100.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,211.26 | 2019-2025 | Mavyret, Linzess, Creon |
| Allergan, INC. | $2,429.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,002.25 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $936.20 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Gilead Sciences, INC. | $892.69 | 2019-2025 | |
| Madrigal Pharmaceuticals | $853.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $742.88 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $695.89 | 2022-2025 | |
| Qol Medical, LLC | $544.75 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $433.55 | 2022-2025 | Dupixent |
| Celgene Corporation | $395.46 | 2022-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $359.35 | 2023-2025 | Iqirvo, Bylvay |
| Nestle Healthcare Nutrition INC. | $316.80 | 2022-2023 | |
| Lilly USA, LLC | $309.31 | 2023-2025 | Omvoh |
| Pfizer INC. | $295.27 | 2019-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $274.38 | 2019-2024 | Linzess |
| Ardelyx, INC. | $199.24 | 2022-2025 | Ibsrela |
| Echosens North America, INC. | $185.40 | 2023 | Fibroscan |
| E.R. Squibb & Sons, L.L.C. | $151.67 | 2022-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $150.06 | 2022-2024 | Dificid |
| Fresenius Kabi USA, LLC | $149.74 | 2023-2024 | Idacio |
| Phathom Pharmaceuticals, INC. | $129.68 | 2023-2024 | Voquezna |
| Celltrion USA INC. | $126.49 | 2023-2025 | Yuflyma, Zymfentra, Vegzelma |
| Lucid Diagnostics INC. | $110.44 | 2021-2024 | |
| Intercept Pharmaceuticals, INC. | $97.81 | 2019-2023 | Ocaliva |
| Aimmune Therapeutics, INC. | $89.77 | 2024-2025 | Zenpep, Vowst |
| Daiichi Sankyo INC. | $76.15 | 2019-2023 | Injectafer |
| Intuitive Surgical, INC. | $73.11 | 2019 | |
| Shionogi INC | $64.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.05 | 2023-2024 | Cyltezo |
| W. L. Gore & Associates, INC. | $51.40 | 2022-2023 | Gore Cardioform Septal Occluder |
| Redhill Biopharma INC. | $51.22 | 2020-2022 | |
| Davol INC. | $49.03 | 2023 | Phasix Mesh |
| Olympus America INC. | $39.75 | 2023-2024 | Endoclot Phs, Visiglide |
| Organon LLC | $34.01 | 2024 | |
| Digestive Care, INC. | $31.98 | 2024 | Pertzye |
| Braintree Laboratories, INC. | $29.20 | 2022-2023 | Sutab |
| Alnylam Pharmaceuticals INC. | $29.00 | 2023 | Givlaari |
| Orphalan INC | $27.33 | 2025 | Cuvrior |
| Medtronic USA, INC. | $26.39 | 2019 | |
| Novo Nordisk INC | $23.54 | 2025 | Wegovy |
| Evoke Pharma, INC. | $20.75 | 2024 | |
| Medtronic, INC. | $18.89 | 2021 | |
| Ferring Pharmaceuticals INC. | $18.66 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.64 | 2024 | Simlandi |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.